← All trials
NCT06320626
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 8, 2022
- Primary completion
- Mar 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Mar 20, 2024
- Last posted
- Mar 20, 2024
- Enrollment
- 95
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Utrecht UniversityLead sponsor
- HagaZiekenhuisCollaborator
- Radboud UniversityCollaborator
- University of AmsterdamCollaborator
- Leiden UniversityCollaborator
- Utrecht UniversitySponsor investigator
- University of GroningenCollaborator
- Erasmus University RotterdamCollaborator
- Utrecht UniversityOfficial
- Maastricht UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.